Drugs / RSS0393
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06308393 | Mar 2024 → Dec 2025 overdue | psoriasis | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07102888 | Aug 2025 → Feb 2026 overdue | psoriasis | Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06918743 | Apr 2025 → Mar 2026 overdue | psoriasis | Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07543224 | Apr 2026 → Jan 2027 expected | psoriasis | Reistone Biopharma Company Limited | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07158151 Comparator | Sep 2025 → Apr 2026 | atopic eczema | Reistone Biopharma Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSS0393 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07158151 ↗ |
| Route | Topical | “Single and Multiple Dose Ascending Local Dermal Administration” NCT06308393 ↗ |